To include your compound in the COVID-19 Resource Center, submit it here.

Biovail acquires Aventis cardiovascular product line

Biovail (BVF; TSE:BVF) will pay $409.5 million for

Read the full 88 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE